Breadcrumb

[A18-59] Dabrafenib (melanoma) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2018-09-24 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 141 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [G19-05] Dabrafenib (melanoma) - Addendum to Commission A18-59
Status: Commission completed

[A17-17] Dabrafenib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A15-39] Dabrafenib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A13-35] Dabrafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2019-01-02 Extract of dossier assessment 141 kBPDFdownload file
2019-01-02 Dossier assessment (German version) 753 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Dabrafenib (melanoma) - Benefit assessment according to §35a Social Code Book V [PDF, 141 kB]

Health information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of advanced melanoma

Federal Joint Committee (G-BA)

2019-03-22 A G-BA decision was published.

G-BA documents on this decision

Press releases

2019-01-02 Melanoma: dabrafenib and trametinib have added benefit



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close